
NYSE:ELAN
This summary was created by AI, based on 2 opinions in the last 12 months.
Elanco Animal Health has recently reported impressive quarterly results, surpassing expectations on multiple fronts. The company's organic sales experienced an 8% increase, signaling robust demand and effective market strategies. Additionally, Elanco has revised its full-year forecast upwards, reflecting confidence in its growth trajectory. Analysts are particularly impressed with the company's turnaround, indicating a strong recovery and strategic improvements. Overall, these developments suggest a positive outlook for Elanco as it continues to refine its approach in the competitive animal health industry.
Spun off from Eli Lilly in 2018. Reported a mixed report today, including their pet business missing as guidance for the current quarter fell short. They will sell its Aqua business to Merck Animal Health, announced restructuring/job cuts and will increase cash flow conversions four times this year, which is a priority. This gives him some hope in the name.
Elanco Animal Health is a American stock, trading under the symbol ELAN (previously ELAN-N on Stockchase) on the New York Stock Exchange (ELAN). It is usually referred to as NYSE:ELAN or ELAN
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on ELAN (previously ELAN-N on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Elanco Animal Health.
Elanco Animal Health was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Elanco Animal Health.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Elanco Animal Health.
Elanco Animal Health is covered by Stockchase experts and is worth watching.
On 2026-09-03, Elanco Animal Health (ELAN) stock closed at a price of $24.42.
Today, they reported a great quarter: beating every metric, organic sales +8%, and raised their full-year forecast.